Feature Article

Atopic Dermatitis: Practical Recommendations for Step-Up Therapy


Although the step-care approach is the current standard of care, this approach is flawed in several ways with respect to achieving optimal outcomes.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News

Skin Hypersensitivity in Infants Decreased With Yogurt Consumption


When testing for sensitivity to histamine, larger swelling sizes were recorded for infants with eczema and atopic dermatitis compared with infants without those conditions.

Emollient Use Helps Reduce Symptoms of Atopic Dermatitis


Continuous treatment with emollient maximizes clinical benefit and should be considered as a first line-treatment for pediatric AD.

Herbal Supplement, Topical Treatment Available for Eczema, Urticaria


Harmony Herbal announced the launch of Skin Therapy Calm over-the-counter (OTC) topical and Calm + Detox supplement duo for the symptomatic relief of rash, eczema, and dermatitis.

Age at Eczema Onset Influences Risk for Pediatric Asthma


Researchers hypothesized that the age of asthma onset in children with early-onset eczema would be younger compared with children with asthma and no eczema.

Dupilumab Effective for Atopic Dermatitis in Patients With Comorbid Asthma

By Pulmonology Advisor Contributing Writer

A recent study showed that the administration of dupilumab was associated with comparable/significant improvement in signs and symptoms of atopic dermatitis in patients with or without comorbid asthma.

Baricitinib 4 mg Effective for Moderate to Severe Atopic Dermatitis


The proportion of participants in the treatment groups who achieved EASI-50 was statistically significant compared with placebo as early as 4 weeks after beginning treatment.

Anti-Inflammatory Moisturizer May Relieve Facial Dermatitis Symptoms

Researchers compared the efficacy of moisturizer containing 4-t-butylcyclohexanol and licochalcone A to 0.02% triamcinolone acetonide (TA) for treating facial dermatitis.

FDA Awards Breakthrough Status to Atopic Dermatitis Treatment


The safety and efficacy of PF-04965842 was evaluated in 375 individuals in a phase 3, randomized, double-blind, placebo-controlled trial.

Severe Atopic Dermatitis May Benefit From Fezakinumab


Despite not reaching significance in the total population, the progressive clinical improvements seen in patients with severe AD suggest a therapeutic advantage.

Refractory Urticaria Benefits From Omalizumab

Omalizumab, alone or in combination with a short-term course of corticosteroids, is highly effective for the treatment of refractory chronic spontaneous urticaria.

Sign up for Newsletters